Obesity and colon cancer

Share This Post

According to a recent study  published in JAMA Oncology, obesity is  associated with an increased risk of early-onset colorectal cancer (CRC) in women.

A medical doctor from Boston Massachusetts General Hospital conducted a study to determine the occurrence of colorectal cancer in 85,256 women without cancer and inflammatory bowel disease based on data from 25-42 -year-old women .

The researchers discovered 114 cases of early-onset CRC (median age at diagnosis, 45 years) during the study period . For overweight women (body mass index [BMI] , 25-29.9 kg / m² ) and obese women (BMI, ≥30 kg / m²) with standard weight ( BMI is 18.5-22.9 kg / m² ) compared with women, CRC increased risk . This finding can be attributed to BMI at 18 years of age and weight gain after 18 years of age. For every 5 units of BMI increase , the RR (relative risk) of colorectal cancer increases by 1.2 . Comparative 18 years old BMI was 18.5-20.9 kg m² / female, BMI is 21 – 22.9 kg / m² women, early onset CRC of RRIs 1.32 , BMI is ≥23kg female RR was 1.63 . Similarly, compared with women who gained less than 5 kg or lost weight, women had an increase of 20-39.9 kg in early-onset CRC with an RR of 1.65 , women with an increase of ≥40 kg and an RR of 2.15.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Gamma Delta T Cell therapy in Sinagpore
CAR T-Cell therapy

Gamma Delta T Cell Therapy in Singapore: A Revolutionary Approach for Late-Stage Cancer Treatment

Gamma Delta (GD) T Cell therapy is revolutionizing stage 4 cancer treatment, offering hope to metastatic cancer patients. At Singapore’s National University Hospital (NUH), the ANGELICA trials harness the unique tumor-targeting abilities of GD T cells. This cutting-edge therapy minimizes side effects, enhances survival rates, and improves quality of life. As a global leader in medical innovation, Singapore positions itself as a premier destination for advanced cancer therapies like GD T Cell therapy.

CAR T Cell therapy for DLBCL in China - A patient story
CAR T-Cell therapy

Indian went to China for CAR T Cell therapy – Patient story

CAR T-cell therapy has emerged as a groundbreaking treatment for diffuse large B-cell lymphoma (DLBCL) in China, offering new hope for patients with relapsed or refractory disease. Approved therapies like Yescarta (axicabtagene ciloleucel) and domestic innovations have made CAR T-cell therapy increasingly accessible. With robust clinical research and government support, China’s advancements in manufacturing and affordability are transforming the landscape, providing patients with cutting-edge, life-saving immunotherapy options.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy